A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression

Prostate

Volumn 70, Issue 10, 2010, Pages 1146-1152

  Xu, Bin ^a   Wang, JinFeng ^b   Tong, Na ^a   Mi, YuanYuan ^a   Min, ZhiChao ^a   Tao, Jun ^a   Li, PengChao ^a   Cheng, Gong ^a   Li, JiuMing ^a   Wang, MeiLin ^a   Tang, JiaLin ^a   Song, NingHong ^a   Zhang, ZhengDong ^a   Zhang, Wei ^a   Wu, HongFei ^a   Hua, LiXin ^a   Feng, NingHan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

MSMB; Polymorphism; Prostate cancer; rs10993994; Serum expression

Indexed keywords

MICROSEMINOPROTEIN BETA; TUMOR PROTEIN; UNCLASSIFIED DRUG; BETA MICROSEMINOPROTEIN; BETA-MICROSEMINOPROTEIN; DNA; PROSTATIC SECRETORY PROTEIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHINESE; CIGARETTE SMOKING; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; BIOSYNTHESIS; BLOOD; CHEMISTRY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; POLYMERASE CHAIN REACTION; PROSTATE TUMOR;

AGED; CASE-CONTROL STUDIES; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS;

EID: 77953384899     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21149     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
2. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91(9):789-794. (Pubitemid 36724060)
3. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13(Spec No 1):R103-121.
4. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40(3):316-321.
5. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED. Tucker M. Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ, Multiple loci identified in a genomewide association study of prostate cancer. Nat Genet 2008; 40(3):310-315.
6. Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dork T, Neal D, Donovan J, Hamdy F, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schurmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O'Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA, Eeles RA. Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008;17(8): 2052-2061.
7. Camp NJ, Farnham JM, Wong J, Christensen GB, Thomas A, Cannon-Albright LA. Replication of the 10q11 and Xp11 prostate cancer risk variants: Results from a Utah pedigree-based study. Cancer Epidemiol Biomarkers Prev 2009;18(4):1290-1294.
8. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, Wacholder S, Chatterjee N, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Ma J, Gaziano JM, Stampfer M, Schumacher FR, Giovannucci E, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Anderson SK, Tucker M, Hoover RN, Fraumeni JF Jr, Thomas G, Hunter DJ, Dean M, Chanock SJ. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA 2009;106(19):7933-7938.
9. Chang BL, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero LM, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Adolfsson J, Liu W, Kim JW, Duggan D, Carpten J, Zheng SL, Rodriguez C, Isaacs WB, Gronberg H, Xu J. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 2009;18(7): 1368-1375.
10. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, DeMarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Isaacs W. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009;69(11):1195-1205.
11. Lee TH, Sakahara NS, Fiebig EW, Hirschkorn DF, Johnson DK, Busch MP. Quantitation of white cell subpopulations by polymerase chain reaction using frozen whole-blood samples. Viral Activation Transfusion Study. Transfusion 1998;38(3):262-270.
12. Garde S, Sheth A, Porter AT, Pienta KJ. Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate 1993;22(3):225-233. (Pubitemid 23184733)
13. Garde SV, Basrur VS, Li L, Finkelman MA, Krishan A, Wellham L, Ben-Josef E, Haddad M, Taylor JD, Porter AT, Tang DG. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999;38(2):118-125.
14. Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003;63(9):2072-2078. (Pubitemid 36546186)
15. Shukeir N, Garde S, Wu JJ, Panchal C, Rabbani SA. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs 2005;16(10):1045-1051.
16. Liu AY, Bradner RC, Vessella RL. Decreased expression of prostatic secretory protein PSP94 in prostate cancer. Cancer Lett 1993;74(1-2):91-99.
17. von der Kammer H, Jurincic-Winkler C, Horlbeck R, Klippel KF, Pixberg HU, Scheit KH. The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor. Urol Res 1993;21(3):227-233. (Pubitemid 23253442)